Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Otonomy (OTIC) PT Lowered to $9 at Cowen Amid Otividex Failure; Dramatic And Fast Changes Needed
August 30, 2017 10:44 AM EDTCowen analyst Ken Cacciatore lowered his price target on Otonomy (NASDAQ: OTIC) to $9.00 (from $55.00) while maintaining an Outperform rating following the Otividex failure.
Cacciatore said said the company will now need to make dramatic and rapid spending reductions and the focus... More
UPDATE: Otonomy (OTIC) Plunges Over 77% After Phase 3 Trial of OTIVIDEX Fails
August 30, 2017 7:33 AM EDT(Updated - August 30, 2017 7:37 AM EDT)
Otonomy (NASDAQ: OTIC) dropped 77% after shares resumed following a brief trading halt pending results for its AVERTS-1 Phase 3 clinical trial of OTIVIDEX in patients with Ménières disease. The clinical trial missed its primary endpoint.
... MoreOtonomy (OTIC) to Resume Trading at 7:30 AM ET
August 30, 2017 7:25 AM EDTOtonomy (NASDAQ: OTIC) to Resume Trading at 7:30 AM ET
... More